Clinical Trial Update: Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of BAY43-9006 (sorafenib) in combination with carboplatin, paclitaxel, and bevacizumab in patients with untreated Stage IIIb non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAY43-9006 (sorafenib)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Status: COMPLETED